The Week in Review: Reckitt Benckiser Plc Buys Anhui's Golong Medicine

by Richard Daverman, PhD

February 23, 2013 -- Reckitt Benckiser, a British maker of OTC drugs, acquired Golong Medicine of Anhui, a TCM company that will provide a base for Reckitt Benckiser’s products in China; China’s SFDA announced a set of newly-revised regulations for the country’s drug distributors to increase the safety of the drug supply chain; Sihuan Pharma received permission from the SFDA to begin clinical trials of an innovative treatment for type 2 diabetes; Regeneron Pharma and Bayer started a new Phase III of a treatment for Diabetic Macular Edema in China; Luye Pharma said its cholesterol-lowering TCM proved effective in a US Phase II clinical trial; and Beijing Double-Crane Pharma will invest $43 million to build a fluid infusion manufacturing facility in Shanghai’s Jinshan Development Park. More details….

Stock Symbols: (HK: 0460) (NSDQ: REGN) (Xetra: BAY) (SGX: A61) (SHE: 600062)

Back to news